Please select the option that best describes you:
Topics:
Radiation Oncology • Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer • Stage III
Would you offer the PACIFIC protocol to a patient with stage III lung cancer with performance status 2-3?
If so, how would you modify this regimen?
Answer from: Medical Oncologist at Community Practice
The PACIFIC trial did not evaluate this regimen in patients with performance status 2-3. Durvalumab dosing does not change based on toxicity. I do not use this regimen for patients with PS 2-3 without supporting data at this time.
Sign in or Register to read more